Humira, Enbrel, Remicade Immunology Drugs Face Stiff Competition in the U.S. from New Biosimilars Due to Patent Expiry
According to a new series of reports on the U.S. market for immunology drugs by iData Research (www.idataresearch.com), projections show a gradual fall in HUMIRA® market share after 2020 due to the entry of infliximab and etanercept biosimilars, as well as other new drugs. The revenues from HUMIRA® currently account for an estimated 34% of the total U.S. immunology drug market. However, since the patent expiry for HUMIRA® in 2016, there are currently two HUMIRA® biosimilars, namely Amjevita™ and Cyltezo™....
View full press release